Differential regulation of CYP1A1 and CYP1B1 expression in resveratrol-treated human medulloblastoma cells

Neuroscience Letters

Volumn 363, Issue 3, 2004, Pages 257-261

  Liu, Jia ^a   Wang, Qian ^a   Wu, Da Chang ^a   Wang, Xiao Wei ^a   Sun, Yuan ^a   Chen, Xiao Yan ^a   Zhang, Kai Li ^a   Li, Hong ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Brain tumor; Chemotherapy; CYP1A1; CYP1B1; Differentiation; Medulloblastoma; Resveratrol

Indexed keywords

CYTOCHROME P450 1A1; CYTOCHROME P450 1B1; ETHOXYRESORUFIN DEETHYLASE; RESVERATROL;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME REGULATION; HUMAN; HUMAN CELL; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; METABOLIC ACTIVATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; UPREGULATION; WESTERN BLOTTING;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL SURVIVAL; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FAS LIGAND PROTEIN; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MEMBRANE GLYCOPROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STILBENES; TIME FACTORS;

EID: 2942534473     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2004.03.075     Document Type: Article

References (22)

1. Aziz M.H., Kumar R., Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int. J. Oncol. 23:2003;17-28
2. Boughton B. Childhood cancer treatment causes complications later in life. Lancet Oncol. 3:2002;390
3. Buratti F.M., Volpe M.T., Meneguz A., Vittozzi L., Testai E. CYP-specific bioactivation of four organophosphorothioate pesticides by human liver microsomes. Toxicol. Appl. Pharmacol. 186:2003;143-154
4. Ciolino H.P., Dankwah M., Yeh G.C. Resistance of MCF-7 cells to dimethylbenz(a)anthracene-induced apoptosis is due to reduced CYP1A1 expression. Int. J. Oncol. 21:2002;385-391
5. Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 58:1998;5707-5712
6. Coumoul X., Diry M., Robillot C., Barouki R. Differential regulation of cytochrome P450 1A1 and 1B1 by a combination of dioxin and pesticides in the breast tumor cell line MCF-7. Cancer Res. 6:2001;3942-3948
7. Dorrie J., Gerauer H., Wachter Y., Zunino S.J. Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res. 61:2001;4731-4739
8. Hose C.D., Hollingshead M., Sausville E.A., Monks A. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro- benzothiazole: a potential surrogate marker for patient sensitivity. Mol. Cancer Ther. 2:2003;1265-1272
9. Keles G.E., Berger M.S., Srinivasan J., Kolstoe D.D., Bobola M.S., Silber J.R. Establishment and characterization of four human medulloblastoma-derived cell lines. Oncol. Res. 7:1995;493-503
10. Le Ferrec E., Lagadic-Gossmann D., Rauch C., Bardiau C., Maheo K., Massiere F., Le Vee M., Guillouzo A., Morel F. Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. J. Biol. Chem. 277:2002;24780-24787
11. Li D., Walcott F.L., Chang P., Zhang W., Zhu J., Petrulis E., Singletary S.E., Sahin A.A., Bondy M.L. Genetic and environmental determinants on tissue response to in vitro carcinogen exposure and risk of breast cancer. Cancer Res. 62:2002;4566-4570
12. Liu J., Guo L., Li J.W., Liu N., Li H. All-trans retinoic acid modulates Fas expression and enhances chemosensitivity of human medulloblastoma cells. Int. J. Mol. Med. 5:2000;145-149
13. Liu J., Wang Q., Wang X., Sun Y., Chen X.Y., Kong Q., Zhang K.L., Li H. Apoptosis of bladder cancer cells induced by short-term and low-dose Mitomycin-C: potential molecular mechanism and clinical implication. Int. J. Mol. Med. 11:2003;389-394
14. McFadyen M.C., Cruickshank M.E., Miller I.D., McLeod H.L., Melvin W.T., Haites N.E., Parkin D., Murray G.I. Cytochrome P450 CYP1B1 over-expression in primary and metastatic ovarian cancer. Br. J. Cancer. 85:2001;242-246
15. McFadyen M.C., McLeod H.L., Jackson F.C., Melvin W.T., Doehmer J., Murray G.I. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem. Pharmacol. 62:2001;207-212
16. Murray G.I. The role of cytochrome P450 in tumour development and progression and its potential in therapy. J. Pathol. 192:2000;419-426
17. Packer R.J., Cogen P., Vezina G., Rorke L.B. Medulloblastoma: clinical and biologic aspects. Neuro-oncology. 1:1999;232-250
18. Pocar P., Augustin R., Fischer B. Constitutive expression of CYP1A1 in bovine cumulus oocyte-complexes in vitro: mechanisms and biological implications. Endocrinology. 145:2004;1594-1601
19. Potter G.A., Patterson L.H., Wanogho E., Perry P.J., Butler P.C., Ijaz T., Ruparelia K.C., Lamb J.H., Farmer P.B., Stanley L.A., Burke M.D. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br. J. Cancer. 86:2002;774-778
20. Toomey B.H., Bello S., Hahn M.E., Cantrell S., Wright P., Tillitt D.E., Di Giulio R.T. 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin induces apoptotic cell death and cytochrome P4501A expression in developing Fundulus heteroclitus embryos. Aquat. Toxicol. 53:2001;127-138
21. Wang Q., Li H., Wang X.W., Wu D.C., Chen X.Y., Liu J. Resveratrol promotes differentiation and induces Fas-independent apoptosis of medulloblastoma cells. Neurosci. Lett. 351:2003;83-86
22. Wieder T., Prokop A., Bagci B., Essmann F., Bernicke D., Schulze-Osthoff K., Dorken B., Schmalz H.G., Daniel P.T., Henze G. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia. 15:2001;1735-1742